What changed
2026-08-04 09:30 UTC → 2026-08-09 09:23 UTC ·
added
removed
Advancements in Alzheimer's blood-test risk prediction blood tests and drug safety
A multinational cohort Research into Alzheimer's biomarkers continues to evolve, with recent findings refining the utility of 2,684 cognitively normal seniors showed that blood-based testing. While plasma p‑tau217 levels identify individuals at markedly higher risk of future cognitive impairment—about p-tau217 remains a 38 % increase over key indicator—showing healthy older adults a one-in-three chance of memory impairment within five years and a 78 % increase over ten years. The findings were presented at the Alzheimer’s Association International Conference in London on 15 July 2026 and published nearly 80% within ten—studies suggest its predictive power in JAMA, with researchers noting that the test symptom-free individuals is not yet recommended for routine screening of asymptomatic people. A follow‑up analysis published in July 2026 confirmed these risk gradients using routine blood samples and reiterated that the biomarker alone does not constitute a diagnosis and must be interpreted with other clinical data. Parallel research reported on 24 July 2026 echoed the same risk figures, stressed the need moderate (AUC = 0.67) compared to combine its high accuracy during the test with clinical assessment, and linked the work to large lifestyle‑intervention trials such as Finland’s FINGER study and its extensions stage. In contrast, biomarkers reflecting amyloid-β protein misfolding have shown higher predictive ability in the Netherlands preclinical phase (AUC = 0.79), and Latin America. The World Health Organization is slated to issue new dementia risk‑reduction guidelines on 16 July, highlighting modifiable factors combining such markers with genetic and demographic data can yield high predictive accuracy (AUC = 0.87). Additionally, an NIH-funded study identified a set of 34 circulating RNAs (circRNAs) that drive the projected rise from 57 million cases may outperform p-tau217 in 2019 forecasting symptom onset two to an estimated 153 million by 2050. On 29 July 2026 Australia’s four years in advance. Clinical implementation is advancing in Australia, where the Therapeutic Goods Administration has approved a rapid p‑tau217 blood test, reporting roughly 90 % diagnostic accuracy and delivering results in about 18 minutes test. Launched at a new Asia‑Pacific the Asia-Pacific Centre of Excellence for Alzheimer’s Diagnosis in Sydney. Sydney, this Roche Diagnostics assay measures pTau181, pTau217, and the ApoE4 genetic risk factor, delivering results in approximately 18 minutes. The test offers a less invasive alternative to PET scans or lumbar punctures and is expected to become be available through via specialist referral within six to nine months, with potential Medicare coverage by year‑end, offering year-end. Regarding treatment, a less invasive alternative to lumbar puncture or PET scans for an estimated 446,500 Australians living with dementia. A German ESTHER cohort real-world study (779 participants, 17‑year follow‑up) by Duke Health involving over 230 patients found that p‑tau217 retains excellent diagnostic accuracy at the FDA-approved drug lecanemab's safety and efficacy align with clinical stage but shows only moderate predictive power in symptom‑free individuals (AUC = 0.67). trials. While 24.3% of participants experienced Amyloid Related Imaging Abnormalities (ARIA), most side effects resolved without hospitalization under close monitoring.